Prescriber Scope of Practice for Narcolepsy in Michigan

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients via telehealth, you’re navigating one of the most complex regulatory intersections in medicine: controlled substance prescribing meets telemedicine meets state-by-state practice authority. The good news? It’s legal in most cases right now. The reality? The rules are in flux, and what works in California won’t fly in Florida.

Let’s cut through the confusion. Here’s what you actually need to know to prescribe stimulants, modafinil, and other narcolepsy medications remotely — without risking your DEA registration or your license.

The Federal Landscape: DEA Rules Are Your Starting Point

Here’s the situation as of 2026: The DEA’s COVID-era telehealth flexibilities are still in effect — extended through December 31, 2026 — allowing you to prescribe Schedule II–V controlled substances via telemedicine without an in-person exam. This includes the amphetamines, methylphenidate, modafinil, and sodium oxybate you’d use for narcolepsy.

What the Ryan Haight Act Actually Says

Normally, federal law (the Ryan Haight Online Pharmacy Act) requires at least one in-person medical evaluation before prescribing any controlled substance via the internet or telemedicine. The law was designed to crack down on rogue online pharmacies, but it caught legitimate telehealth in its net.

The catch: The DEA has repeatedly postponed enforcing this requirement. First during the COVID Public Health Emergency, then through a series of temporary extensions (most recently announced January 2026), the agency has maintained that providers can establish a patient relationship and prescribe controlled substances entirely via telehealth — as long as you’re otherwise compliant (proper state licensure, DEA registration, legitimate medical purpose, standard of care).

What Happens When the Extension Expires?

The DEA has been working on permanent telemedicine rules since 2022. Their initial proposal in 2023 — requiring an in-person visit after an initial 30-day telemedicine prescription for Schedule II drugs — drew over 38,000 public comments and strong pushback. The agency shelved it.

What to expect: The final rules (likely sometime in 2025–2026) will probably allow some form of telehealth prescribing for controlled substances, but with guardrails. Possibilities include:

• Initial 30-day supply limits before requiring follow-up (in-person or with additional verification)
• Condition-specific exceptions (like the buprenorphine carve-out for opioid use disorder finalized in January 2025)
• Special registration requirements for telemedicine prescribers

Bottom line for narcolepsy providers: You’re operating under a temporary safe harbor that gives you through 2026. Use this window to build your practice, but have a contingency plan. Consider hybrid models — partnering with local sleep labs or clinics for initial diagnostic workups (polysomnography and MSLT testing often need to be in-person anyway) and maintaining documentation that would support medical necessity if audited.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Reality Check: Where Telehealth Narcolepsy Care Gets Complicated

Federal rules are just the floor. States add their own layers — and for narcolepsy, Florida is the major outlier you need to know about.

Florida: The Telehealth Prescribing Exception That Doesn’t Include Narcolepsy

Florida’s telehealth statute (§456.47) explicitly prohibits prescribing Schedule II controlled substances via telemedicine — except for treating psychiatric disorders, inpatient hospital care, hospice, or nursing home residents.

The problem: Narcolepsy isn’t a psychiatric disorder. It’s a neurological sleep disorder. That means:

• A Florida-licensed psychiatrist cannot legally prescribe Adderall or other Schedule II stimulants for narcolepsy via pure telehealth
• You’d need at least one in-person visit to stay compliant with state law
• You can prescribe modafinil (Schedule IV) via telehealth in Florida — the law only restricts Schedule II and III

Workaround strategies Florida providers use:

• Start patients on modafinil (armodafinil) remotely as first-line
• Require an in-person consultation (either with you or a collaborating provider) before initiating stimulants
• Partner with brick-and-mortar sleep centers for initial evaluations
• For PMHNPs: Remember Florida’s 7-day limit on Schedule II prescriptions (unless you’re a designated ‘psychiatric nurse’ treating mental illness — which doesn’t apply to narcolepsy)

New York: Following Federal Law (For Now)

New York finalized regulations in May 2025 that require an in-person exam before prescribing controlled substances via telehealth — unless you’re complying with federal law or meet specific exceptions (patient recently seen in person by another provider, covering for an established patient, etc.).

Since federal law currently allows it (via the DEA extension), you’re good to go in New York through 2026. When federal rules tighten, New York’s requirement will automatically kick back in — meaning you’ll need to meet one of those exceptions or arrange an in-person component.

Advantage for PMHNPs: New York grants full practice authority to experienced NPs (those with 3,600+ hours). An independent PMHNP can handle the entire narcolepsy care pathway in NY — diagnosis, prescribing Schedule IIs, ongoing management — without physician oversight. Just remember to check the I-STOP PDMP and use electronic prescribing.

Texas: Where NPs Hit a Wall

Texas allows telehealth prescribing via live video and doesn’t ban controlled substances for narcolepsy specifically (the state law banning telehealth controlled substances applies to chronic pain management, not narcolepsy).

But here’s the NP constraint: Texas law prohibits APRNs from prescribing Schedule II controlled substances in outpatient settings — period. The only exceptions are hospital admissions, emergency departments, or hospice care.

What this means:

• Psychiatrists: You can evaluate and prescribe narcolepsy stimulants via telehealth in Texas (following DEA rules)
• PMHNPs: You can prescribe modafinil (Schedule IV) under a physician delegation agreement, but you cannot prescribe methylphenidate or amphetamines for outpatient narcolepsy patients. A supervising physician must write those prescriptions.

If you’re building a Texas telehealth practice focusing on narcolepsy, you either need psychiatrists on your team or a collaborative model where physicians handle Schedule II prescriptions.

California, Pennsylvania, Illinois: More Flexibility

California: Full practice authority for experienced NPs (4,600+ hours under AB 890). PMHNPs can prescribe Schedule II independently once certified. No state-specific telehealth restrictions beyond federal law. Must check CURES PDMP before every controlled substance prescription.

Pennsylvania: NPs need physician collaboration and are limited to 30-day Schedule II prescriptions (physician involvement required for continuation). No special telehealth ban on narcolepsy meds. Standard video exam suffices under DEA rules. Must query PA PDMP.

Illinois: Full practice authority for NPs after 4,000 hours + additional training. Independent NPs can prescribe Schedule II–V for narcolepsy. Illinois requires electronic prescribing for all controlled substances (since January 2023) and PDMP checks. No state telehealth restrictions beyond federal.

Psychiatrists vs PMHNPs: Scope of Practice for Narcolepsy

Psychiatrists: Full Authority, No Scope Questions

As an MD or DO, you have independent prescriptive authority in all states (with proper DEA registration). No one questions whether a psychiatrist can treat narcolepsy — it’s within your scope as long as you’re practicing competently.

Practical considerations:

• Narcolepsy diagnosis often requires polysomnography and Multiple Sleep Latency Testing (MSLT) — you’ll need relationships with sleep labs in your patients’ areas
• Some states (like Florida) explicitly list narcolepsy as an approved indication for stimulants in their medical practice regulations — protecting you from overprescribing allegations
• Document your clinical reasoning thoroughly: why this patient needs a Schedule II vs Schedule IV, your PDMP check, your risk assessment

PMHNPs: State-Dependent Authority

Your ability to treat narcolepsy independently varies dramatically:

Full Authority States (CA, NY, IL post-experience):

• Can diagnose narcolepsy and prescribe all necessary medications independently
• Must meet state-specific requirements (hours of practice, additional certifications, DEA registration, PDMP enrollment)
• Same standard of care as physicians — coordinate diagnostic testing, document thoroughly

Restricted/Reduced States (TX, FL, PA):

• Need physician collaboration or delegation agreements
• May face formulary restrictions (Florida’s 7-day Schedule II limit, Texas’s complete ban on outpatient Schedule II for NPs)
• Physician must often write Schedule II prescriptions or co-sign treatment plans
• Can prescribe Schedule III–IV (modafinil, sodium oxybate) under delegation in most cases

The reality: Even in restricted states, experienced PMHNPs often manage the clinical care (evaluation, diagnosis, monitoring) with a supervising physician handling specific prescription elements. It’s not ideal, but it expands access.

The Economics: What Actually Makes Sense for Your Practice

Let’s be honest about patient acquisition costs. You’re not going to acquire narcolepsy patients for $30–50 like some marketing materials claim.

Reality check on DIY marketing:

• SEO: Takes 6–12 months of consistent investment ($1,500–3,000/month for content, technical optimization, local listings) before you see meaningful patient flow. Most solo providers don’t have this runway.
• Google Ads: Mental health keywords run $15–40+ per click. Factor in that most clicks don’t convert to booked appointments, and you’re looking at $200–400+ per actual booked patient. Add in no-shows from cold leads, and your real acquisition cost climbs higher.
• Directory listings (Psychology Today, Zocdoc): Monthly fees plus per-booking charges. Zocdoc charges $35–100+ per booking, plus a monthly subscription. You’re competing with hundreds of other providers on the same page.
• Total monthly marketing spend for a solo practice trying to build volume: $3,000–5,000+ with uncertain, delayed results.

The platform model (like Klarity Health):

• Pay-per-appointment structure — you only pay when a qualified patient books with you
• No upfront marketing spend or monthly subscriptions
• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate EHR, video platform, or e-prescribing costs)
• Both insurance and cash-pay patient flow
• You control your schedule and only pay for patients you actually see

The math: Instead of gambling $3,000–5,000/month on marketing channels that might work eventually, you pay a standard listing fee per new patient lead. That’s guaranteed ROI — you know your patient acquisition cost for every appointment. For providers building a narcolepsy practice (a specialty with limited patient volume and complex regulations), eliminating marketing risk makes economic sense.

Practical Compliance: What You Actually Need to Do

Before You See Your First Narcolepsy Patient via Telehealth:

Licensing & Registration:

• Active medical license in the state where your patient is located
• DEA registration with Schedule II authority (and state-level controlled substance registration if required — like New York’s Bureau of Narcotic Enforcement registration)
• State PDMP enrollment and system access (mandatory in all six states discussed)
• Malpractice insurance that covers telehealth and controlled substance prescribing

Technology & Documentation:

• HIPAA-compliant telehealth platform (video required in most states; Texas explicitly mandates two-way audio-visual for controlled substance prescribing)
• Electronic prescribing system with two-factor authentication (required for Schedule II in most states; Illinois and New York mandate e-prescribing for all controlled substances)
• EHR integration with state PDMP (you’ll need to check before every stimulant prescription)

Clinical Protocols:

• Informed consent process for telehealth (state-specific requirements)
• Identity verification procedures
• Documentation standards: your telehealth exam must be as thorough as in-person (history, review of systems, mental status exam, relevant physical exam elements observable via video)
• Emergency protocols: what happens if a patient has an adverse reaction or crisis?

For Every Narcolepsy Patient Encounter:

1. PDMP Check: Query your state’s prescription monitoring program before prescribing any controlled substance. Document what you found. (California requires this every 4 months for ongoing therapy; most other states require it at least for initial prescriptions and periodically thereafter.)

2. Document Clinical Justification: Why does this patient have narcolepsy (sleep study results)? Why does this patient need a Schedule II stimulant vs alternatives? What’s your risk assessment (history of substance use, diversion risk, psychiatric comorbidities)?

3. Follow State-Specific Rules:

• Florida: If you’re prescribing a Schedule II, document that narcolepsy is the indication (it’s on the state’s approved list)
• Texas: Use live video, not audio-only
• New York: Check I-STOP, use e-prescribing, document compliance with telehealth exception
• Pennsylvania: If you’re a CRNP, ensure your 30-day limit and physician consultation requirements are met

1. Standard of Care: Just because it’s telehealth doesn’t mean you skip steps. If you wouldn’t start Adderall without confirming a diagnosis via sleep study in person, don’t do it via video. Coordinate with sleep labs, review external records, use validated screening tools (Epworth Sleepiness Scale), and schedule appropriate follow-ups.

2. Risk Management: Stimulants have abuse potential. Sodium oxybate has a strict FDA REMS program (you must be specially enrolled). Document your monitoring plan: how often will you see the patient, what metrics will you track, when will you adjust doses or discontinue?

What’s Coming: Preparing for Post-2026 Rules

The DEA will eventually finalize permanent telemedicine rules. Here’s how to position yourself:

Build Hybrid Relationships Now:

• Establish referral networks with sleep labs in states where you see patients
• Consider partnerships with primary care clinics or neurologists who can provide in-person exams if needed
• Document your care coordination — showing you’re not operating in a silo strengthens your position if regulations tighten

Stay Informed:

• Subscribe to DEA and state medical board updates
• Join professional organizations (American Psychiatric Association, American Academy of Sleep Medicine, AANP for NPs) that track regulatory changes
• Monitor Federal Register notices for proposed DEA rules and comment when they come out

Be Ready to Adapt:

• If DEA mandates an in-person exam within 30 days of initial telehealth prescription, can you facilitate that for your patients?
• If certain medications (like high-dose stimulants) require in-person management, do you have a plan to transition care or add that component?
• If ‘special registration’ for telemedicine prescribing becomes available, apply early

Document Everything:

• The better your clinical documentation now, the easier it will be to demonstrate you’ve been practicing to a high standard when new rules take effect
• Audits happen — state medical boards and DEA can review prescribing patterns. Thorough notes protect you

The Bottom Line: Can You Build a Telehealth Narcolepsy Practice?

Yes, in most states — with caveats:

• Psychiatrists have the most flexibility. You can diagnose and prescribe Schedule II stimulants via telehealth in California, Texas, New York, Pennsylvania, and Illinois right now (through 2026 under federal rules). Florida requires workarounds.

• PMHNPs can fully manage narcolepsy in states with full practice authority (California post-4,600 hours, New York post-3,600 hours, Illinois with FPA). In restricted states (Texas, Florida, Pennsylvania), you’ll need physician collaboration and may be limited on Schedule II prescriptions — but you can still play a major clinical role.

• The regulatory window is open but temporary. Use 2025–2026 to build your practice, establish patient relationships, and create sustainable care models. When federal rules tighten, providers with thoughtful compliance systems and hybrid care models will be best positioned.

• Economics favor platforms over DIY marketing for most providers. Unless you have significant capital, patience for 6–12 month SEO timelines, and expertise in healthcare marketing, paying per qualified patient makes more financial sense than gambling thousands per month on uncertain marketing channels.

Narcolepsy is underserved. There aren’t enough sleep specialists to meet demand. Patients wait months for appointments. Telehealth — especially with psychiatrists and PMHNPs who are comfortable managing stimulants and other controlled medications — can genuinely expand access. Just do it compliantly, document thoroughly, and stay ahead of regulatory changes.

Frequently Asked Questions

Can I prescribe Adderall or Ritalin for narcolepsy via telehealth without ever meeting the patient in person?

As of 2026, yes — under the DEA’s temporary extension through December 31, 2026. Exception: Florida state law prohibits prescribing Schedule II stimulants via telehealth for narcolepsy (only allowed for psychiatric disorders). In all other states discussed here, you can prescribe Schedule II stimulants remotely as long as you conduct a proper video evaluation and meet all standard prescribing requirements (DEA registration, state license, PDMP check, etc.). When the DEA extension expires, you’ll likely need at least one in-person exam or use another approved exception.

What’s the difference between how psychiatrists and PMHNPs can treat narcolepsy?

Psychiatrists (MD/DO) have independent prescriptive authority in all states — no scope questions or formulary restrictions beyond standard prescribing rules. PMHNPs’ authority varies by state: full independence in California (after experience), New York, and Illinois; physician collaboration required in Pennsylvania; severe restrictions in Texas (can’t prescribe Schedule II outpatient) and Florida (7-day limit on Schedule II unless treating mental illness). The clinical competency is comparable, but the legal authority differs.

Do I need a DEA ‘special registration’ to prescribe controlled substances via telehealth?

Not yet. The DEA has discussed creating a telemedicine special registration system but hasn’t implemented it as of early 2026. You need a standard DEA registration with Schedule II authority and must be licensed in the state where your patient is located. The temporary flexibilities (extended through 2026) allow you to prescribe via telehealth without additional federal registration beyond your existing DEA number.

What happens if the DEA flexibilities expire and I have ongoing narcolepsy patients on stimulants?

Existing patient relationships established under the temporary rules would likely be grandfathered or subject to a transition period — the DEA indicated in past guidance that they don’t intend to disrupt ongoing legitimate care. However, you should prepare for potential new requirements (like arranging an in-person exam within 30 days of a regulation change, or using one of the Ryan Haight Act exceptions such as having a consulting provider see the patient in person). Monitor DEA announcements and have contingency plans to maintain continuity of care for your patients.

Can I treat narcolepsy patients in multiple states via telehealth?

Yes, if you hold an active medical license in each state where your patients are located. Telemedicine doesn’t exempt you from state licensing requirements. Many providers use the Interstate Medical Licensure Compact (IMLC) to expedite getting licensed in multiple states — Illinois, Texas, and Pennsylvania are members. California, New York, and Florida are not in the IMLC, so you’ll need to apply for licensure through each state’s individual process. You’ll also need to comply with each state’s specific telehealth and prescribing rules (which is why Florida’s restrictions on Schedule II via telehealth can limit your practice even if you’re licensed there).

How do I coordinate sleep studies for narcolepsy diagnosis if I’m practicing via telehealth?

Build referral relationships with accredited sleep centers in the regions where you see patients. You’ll need diagnostic confirmation (polysomnography and MSLT) to justify prescribing controlled substances long-term — starting stimulants based solely on patient-reported symptoms without objective testing doesn’t meet the standard of care and puts your prescribing at risk. Many sleep centers accept referrals from out-of-state telemedicine providers as long as you’re appropriately licensed. Document the diagnostic results in your records and ensure the sleep study report supports your narcolepsy diagnosis.

Ready to Expand Access to Narcolepsy Care via Telehealth?

Navigating the regulatory landscape for controlled substance prescribing is complex, but the opportunity to serve underserved narcolepsy patients is real — and the economics of platform-based practice make more sense than spending months and thousands of dollars on DIY marketing.

Klarity Health connects psychiatrists and PMHNPs with pre-qualified patients seeking narcolepsy care via telehealth. Our pay-per-appointment model eliminates upfront marketing costs, our compliance infrastructure handles state-specific regulations, and our telehealth platform integrates everything you need (video, EHR, e-prescribing, PDMP access).

You control your schedule. You only pay when you see patients. And you practice medicine — not marketing.

Explore joining Klarity’s provider network and start seeing narcolepsy patients in your licensed states within weeks, not months.

References and Sources

1. U.S. Department of Health and Human Services (HHS) Press Release — ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026). Available at: https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration (DEA) — ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (November 15, 2024). Available at: https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

3. U.S. Drug Enforcement Administration (DEA) — ‘DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care’ (December 31, 2025). Available at: https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care

4. 21 U.S. Code §829(e) — Ryan Haight Online Pharmacy Consumer Protection Act (definitions of in-person medical evaluation and telemedicine). Legal Information Institute, Cornell Law School. Available at: https://www.law.cornell.edu/definitions/uscode.php?def_id=21-USC-1796173870-113781527

5. Nixon Peabody LLP Legal Alert — ‘New York State Finalizes Telemedicine Rule for Controlled Substances’ (June 18, 2025). Available at: https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances

This content is for informational purposes and does not constitute legal or medical advice. Providers should consult their state medical boards, DEA regional offices, and legal counsel for specific guidance on telehealth prescribing and scope of practice. Regulations are subject to change.

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206